COMMD4 Drives Skin Cutaneous Melanoma Progression by Targeting PI3K‐p85 to Activate PI3K‐AKT
Annals of the New York Academy of Sciences · 2026
DOI: 10.1111/nyas.70141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the New York Academy of Sciences, 2026. Verfasst von Xiaoqiang Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Melanoma, Skin Neoplasms, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Chongqing Clinical Key Specialty Construction Project, Chongqing Medical Leading Talent Project: YXLJ202414, Xinjiang Autonomous Region Youth Science Foundation.
Abstract (Originalsprache)
Skin cutaneous melanoma (SKCM), the most aggressive form of cutaneous malignancy globally, remains poorly understood in terms of its molecular drivers. Although the copper metabolism MURR1 domain (COMMD) protein family has been associated with oncogenesis, its functional relevance in SKCM is undefined. In this study, we identified COMMD4 as a prognostic biomarker of SKCM and showed that it is positively correlated with the adverse clinical outcomes of patients. COMMD4 gene knockout (COMMD4‐KO) impaired the proliferative, migratory, and invasive capacities of SKCM cells in vitro and suppressed xenograft tumor growth in vivo. Mechanistically, COMMD4‐KO induced G2/M phase arrest by disrupting p21‐CDK1‐cyclinB1 and impeded epithelial‐mesenchymal transition (EMT) by reversing the E/N cadherin switch. We also demonstrate that COMMD4 activates PI3K‐AKT signaling by binding PI3K‐p85 to release PI3K‐p110, thereby driving G2/M transition and EMT. Reactivation of PI3K‐AKT signaling in COMMD4‐KO cells rescued oncogenic phenotypes. By integrative Connectivity Map analysis and functional validation, we identified triamterene as a pharmacological inhibitor targeting the COMMD4‐PI3K‐AKT axis, which suppressed the progression of SKCM effectively in vitro and vivo. Our findings establish the COMMD4‐PI3K‐AKT axis as a novel and critical regulator of SKCM progression and repurpose triamterene as a promising therapeutic agent against SKCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
- Department of Plastic Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), National Key Laboratory of Trauma and Chemical Poisoning, Chongqing, China.
- Department of Burn and Plastic Surgery, PLA 77th Group Army Hospital, Leshan, China.
- Department of Plastic Surgery, General Hospital of Xinjiang Military Command, Urumqi, China.
ORCID-Profile: Boye Qi
Förderung
- Chongqing Clinical Key Specialty Construction Project
- Chongqing Medical Leading Talent Project: YXLJ202414
- Xinjiang Autonomous Region Youth Science Foundation
Zitieren
APA
Liu, X., Liu, L., Wang, Q., Xia, L., Zuo, F., Yang, J., Zheng, K., Tang, Y., Guo, J., Yu, X., Qi, B., Zhou, H., Chen, Y., Zhang, J., & Zhang, X. (2026). COMMD4 Drives Skin Cutaneous Melanoma Progression by Targeting PI3K‐p85 to Activate PI3K‐AKT. Annals of the New York Academy of Sciences. https://doi.org/10.1111/nyas.70141
Vancouver
Liu X, Liu L, Wang Q, Xia L, Zuo F, Yang J, et al. COMMD4 Drives Skin Cutaneous Melanoma Progression by Targeting PI3K‐p85 to Activate PI3K‐AKT. Annals of the New York Academy of Sciences. 2026. doi:10.1111/nyas.70141
BibTeX
@article{Liu2026,
author = {Liu, Xiaoqiang and Liu, Luojia and Wang, Qiaoling and Xia, Lufan and Zuo, Fangqing and Yang, Jinrui and Zheng, Kaibang and Tang, Yunfan and Guo, Jingjing and Yu, Xiaoping and Qi, Boye and Zhou, Hanghang and Chen, Ying and Zhang, Jiaping and Zhang, Xuanfen},
title = {COMMD4 Drives Skin Cutaneous Melanoma Progression by Targeting PI3K‐p85 to Activate PI3K‐AKT},
journal = {Annals of the New York Academy of Sciences},
year = {2026},
doi = {10.1111/nyas.70141}
}
EUVIMED